Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 10.74
(1.32%)
AUD 10.74
(1.32%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 31.29 Million AUD | 223.33% |
| 2023 | 9.67 Million AUD | -28.48% |
| 2022 | 13.53 Million AUD | 59.06% |
| 2021 | 8.5 Million AUD | 3.33% |
| 2020 | 8.23 Million AUD | -36.81% |
| 2019 | 13.03 Million AUD | 10.1% |
| 2018 | 11.83 Million AUD | 27.26% |
| 2017 | 9.3 Million AUD | 12.79% |
| 2016 | 8.24 Million AUD | 0.9% |
| 2015 | 8.17 Million AUD | 0.35% |
| 2014 | 8.14 Million AUD | -17.19% |
| 2013 | 9.83 Million AUD | -10.84% |
| 2012 | 11.02 Million AUD | -19.92% |
| 2011 | 13.77 Million AUD | -15.91% |
| 2010 | 16.37 Million AUD | -9.97% |
| 2009 | 18.19 Million AUD | -3.49% |
| 2008 | 18.84 Million AUD | 63.09% |
| 2007 | 11.55 Million AUD | -0.85% |
| 2006 | 11.65 Million AUD | -6.4% |
| 2005 | 12.45 Million AUD | 42.58% |
| 2004 | 8.73 Million AUD | 78.0% |
| 2003 | 4.9 Million AUD | 18.34% |
| 2002 | 4.14 Million AUD | 11419.44% |
| 2001 | 36 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 30.09 Million AUD | 210.87% |
| 2024 Q2 | 5.58 Million AUD | 0.0% |
| 2024 Q4 | 15.41 Million AUD | 0.0% |
| 2023 Q4 | 5.56 Million AUD | 0.0% |
| 2023 FY | 9.67 Million AUD | -28.48% |
| 2023 Q2 | 7.94 Million AUD | 0.0% |
| 2022 FY | 13.53 Million AUD | 59.06% |
| 2022 Q2 | 6.62 Million AUD | 0.0% |
| 2022 Q4 | 6.93 Million AUD | 0.0% |
| 2021 FY | 8.5 Million AUD | 3.33% |
| 2021 Q2 | 9.53 Million AUD | 0.0% |
| 2021 Q4 | 11.72 Million AUD | 0.0% |
| 2020 Q4 | 11.93 Million AUD | 0.0% |
| 2020 Q2 | 8.06 Million AUD | 0.0% |
| 2020 FY | 8.23 Million AUD | -36.81% |
| 2019 Q2 | 4.99 Million AUD | 0.0% |
| 2019 Q4 | 8.67 Million AUD | 0.0% |
| 2019 FY | 13.03 Million AUD | 10.1% |
| 2018 FY | 11.83 Million AUD | 27.26% |
| 2018 Q4 | 6.26 Million AUD | 0.0% |
| 2018 Q2 | 5.56 Million AUD | 0.0% |
| 2017 Q2 | 4.4 Million AUD | 0.0% |
| 2017 FY | 9.3 Million AUD | 12.79% |
| 2017 Q4 | 4.89 Million AUD | 0.0% |
| 2016 Q4 | 3.37 Million AUD | 0.0% |
| 2016 FY | 8.24 Million AUD | 0.9% |
| 2016 Q2 | 4.87 Million AUD | 0.0% |
| 2015 FY | 8.17 Million AUD | 0.35% |
| 2015 Q4 | 312.73 Thousand AUD | 0.0% |
| 2015 Q2 | 8.48 Million AUD | 0.0% |
| 2014 Q2 | 4.17 Million AUD | 0.0% |
| 2014 Q4 | 3.97 Million AUD | 0.0% |
| 2014 FY | 8.14 Million AUD | -17.19% |
| 2013 Q3 | 158.59 Thousand AUD | -97.09% |
| 2013 Q4 | 4.08 Million AUD | 2474.21% |
| 2013 FY | 9.83 Million AUD | -10.84% |
| 2013 Q1 | 152.83 Thousand AUD | 0.0% |
| 2013 Q2 | 5.45 Million AUD | 3468.8% |
| 2012 Q2 | 152.83 Thousand AUD | -35.38% |
| 2012 FY | 11.02 Million AUD | -19.92% |
| 2012 Q4 | 152.83 Thousand AUD | 0.0% |
| 2012 Q3 | 152.83 Thousand AUD | 0.0% |
| 2012 Q1 | 236.5 Thousand AUD | 0.0% |
| 2011 Q1 | 425.88 Thousand AUD | 0.0% |
| 2011 Q2 | 236.5 Thousand AUD | -44.47% |
| 2011 FY | 13.77 Million AUD | -15.91% |
| 2011 Q3 | 236.5 Thousand AUD | 0.0% |
| 2011 Q4 | 236.5 Thousand AUD | 0.0% |
| 2010 Q2 | 425.88 Thousand AUD | 444.48% |
| 2010 Q4 | 425.88 Thousand AUD | 0.0% |
| 2010 FY | 16.37 Million AUD | -9.97% |
| 2010 Q1 | 78.21 Thousand AUD | 0.0% |
| 2010 Q3 | 425.88 Thousand AUD | 0.0% |
| 2009 Q1 | 576.02 Thousand AUD | 0.0% |
| 2009 Q3 | 78.21 Thousand AUD | 0.0% |
| 2009 Q2 | 78.21 Thousand AUD | -86.42% |
| 2009 Q4 | 78.21 Thousand AUD | 0.0% |
| 2009 FY | 18.19 Million AUD | -3.49% |
| 2008 Q2 | 576.02 Thousand AUD | -78.37% |
| 2008 Q1 | 2.66 Million AUD | 0.0% |
| 2008 FY | 18.84 Million AUD | 63.09% |
| 2008 Q4 | 576.02 Thousand AUD | 0.0% |
| 2008 Q3 | 576.02 Thousand AUD | 0.0% |
| 2007 Q3 | 2.66 Million AUD | 0.0% |
| 2007 Q2 | 2.66 Million AUD | 946.11% |
| 2007 FY | 11.55 Million AUD | -0.85% |
| 2007 Q1 | 254.56 Thousand AUD | 0.0% |
| 2007 Q4 | 2.66 Million AUD | 0.0% |
| 2006 FY | 11.65 Million AUD | -6.4% |
| 2006 Q3 | 254.56 Thousand AUD | 0.0% |
| 2006 Q1 | 590.98 Thousand AUD | 0.0% |
| 2006 Q4 | 254.56 Thousand AUD | 0.0% |
| 2006 Q2 | 254.56 Thousand AUD | -56.93% |
| 2005 Q2 | 590.98 Thousand AUD | -70.25% |
| 2005 Q4 | 590.98 Thousand AUD | 0.0% |
| 2005 Q3 | 590.98 Thousand AUD | 0.0% |
| 2005 Q1 | 1.98 Million AUD | 0.0% |
| 2005 FY | 12.45 Million AUD | 42.58% |
| 2004 Q3 | 1.98 Million AUD | 0.0% |
| 2004 Q4 | 1.98 Million AUD | 0.0% |
| 2004 FY | 8.73 Million AUD | 78.0% |
| 2004 Q1 | 423.33 Thousand AUD | 0.0% |
| 2004 Q2 | 1.98 Million AUD | 369.19% |
| 2003 Q1 | 468 Thousand AUD | 0.0% |
| 2003 FY | 4.9 Million AUD | 18.34% |
| 2003 Q3 | 423.33 Thousand AUD | 0.0% |
| 2003 Q4 | 423.33 Thousand AUD | 0.0% |
| 2003 Q2 | 423.33 Thousand AUD | -9.54% |
| 2002 Q3 | 468 Thousand AUD | 0.0% |
| 2002 Q2 | 468 Thousand AUD | 540.21% |
| 2002 Q4 | 468 Thousand AUD | 0.0% |
| 2002 Q1 | 73.1 Thousand AUD | 0.0% |
| 2002 FY | 4.14 Million AUD | 11419.44% |
| 2001 Q3 | 73.1 Thousand AUD | 0.0% |
| 2001 Q2 | 73.1 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | 36 Thousand AUD | 0.0% |
| 2001 Q4 | 73.1 Thousand AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -362.324% |
| Biome Australia Limited | 7.91 Million AUD | -295.603% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -10359.259% |
| Biotron Limited | 5.11 Million AUD | -512.385% |
| Acrux Limited | 8.55 Million AUD | -266.047% |
| Alterity Therapeutics Limited | 23.4 Million AUD | -33.71% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -5100.397% |
| BTC Health Limited | -1.03 Million AUD | 3112.438% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -58.327% |
| CSL Limited | 7.56 Billion AUD | 99.586% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 44.417% |
| Immutep Limited | 42.87 Million AUD | 27.004% |
| Memphasys Limited | 3.67 Million AUD | -750.837% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 4.282% |
| Noxopharm Limited | 7 Million AUD | -347.088% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -187.161% |
| Race Oncology Limited | 14.77 Million AUD | -111.889% |
| Starpharma Holdings Limited | 22.81 Million AUD | -37.171% |
| Tissue Repair Ltd | 6.66 Million AUD | -369.445% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 20.916% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -4306.686% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -1033.534% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -426.132% |
| Patrys Limited | 4.93 Million AUD | -534.402% |
| Orthocell Limited | 15.36 Million AUD | -103.63% |
| Imugene Limited | 135.09 Million AUD | 76.833% |
| PYC Therapeutics Limited | 60.91 Million AUD | 48.623% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -3408.073% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -181.358% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -190.183% |
| Nanollose Limited | 12.5 Thousand AUD | -250256.22% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -835.389% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -1492.545% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -271.006% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -658.65% |
| Nyrada Inc. | 4.55 Million AUD | -587.066% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 88.377% |
| Dimerix Limited | 25.64 Million AUD | -22.048% |
| PharmAust Limited | 6.65 Million AUD | -370.138% |
| Hexima Limited | 1 Million AUD | -3002.556% |
| AnteoTech Limited | 12.18 Million AUD | -156.807% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 51.927% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -44.329% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -588.544% |
| Actinogen Medical Limited | 22.77 Million AUD | -37.446% |
| Immuron Limited | 9.13 Million AUD | -242.496% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -278.48% |